FLUBLOK QUADRIVALENT Rx
Generic Name and Formulations:
Quadrivalent, recombinant hemagglutinin (virus types A and B); contains a total of 180mcg recombinant hemagglutinin per 0.5mL dose; formulation changes annually; soln for IM inj; egg-, antibiotic-, preservative-free.
Sanofi Pasteur, Inc.
Indications for FLUBLOK QUADRIVALENT:
≥18yrs: 0.5mL by IM inj once in the deltoid.
3–<18yrs: not established.
Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Have appropriate treatment available to manage anaphylaxis. Pregnancy. Nursing mothers.
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants: may get suboptimal response.
Inj site tenderness and pain, headache, fatigue, myalgia, arthralgia.
Single-dose prefilled syringes (0.5mL)—10
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness